

1 **Title Page:**

2 **Metabolic dysfunction-associated steatohepatitis is associated with increased all-**
3 **cause mortality**

4

5 **Running title:** MASH can increase the risk of all-cause mortality

6

7 Zhao Li^{1#}, Rui Song^{2#}, Yingzhi Zhang^{2#}, Jiahe Tan³, Zhiwei Chen^{2*}

8

9 ¹ Department of Gastroenterology, the Seventh People's Hospital of Chongqing,
10 Chongqing, China.

11 ² Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of
12 Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the
13 Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

14 ³ Department of Neurosurgery, the First Affiliated Hospital of Chongqing Medical
15 University, Chongqing, China.

16

17 # These authors contribute equally to this work.

18 * Corresponding author. Address: Institute for Viral Hepatitis, The Key Laboratory of
19 Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The
20 Second Affiliated Hospital of Chongqing Medical University, 74 Linjiang Road,
21 Yuzhong District, Chongqing 400010, China. E-mail addresses:

22 zhiwei_chen@cqmu.edu.cn.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23

24 **Author's email address:**

25 Zhao Li: 1546866602@qq.com

26 Rui Song: sr202099@163.com

27 Yingzhi Zhang: zhangyingzhi217@163.com

28 Jiahe Tan: tanjiahe1995@163.com

29 Zhiwei Chen: zhiwei_chen@cqmu.edu.cn

30

31 **Data Availability Statement:** All the data in this study were available in the

32 NHANES III public database.

33

34 **Funding:** This work was supported by Remarkable Innovation-Clinical Research

35 Project, The Second Affiliated Hospital of Chongqing Medical University, and The

36 First batch of key Disciplines on Public Health in Chongqing, Health Commission of

37 Chongqing, China.

38

39 **Conflict of interest statement:** The authors declare no conflicts of interest.

40

41 **Ethics approval statement and patient consent statement:** NHANES III was

42 approved by the CDC/NCHS Ethics Review Board, and all individuals signed

43 informed consent to participate in NHANES III.

44

45 **Permission to reproduce material from other sources:** Yes.

46

47 **Clinical trial registration:** Not applicable.

48

49 **Word count:** 4026.

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67 **Abstract**

68 **Background:** Recently, the new nomenclature metabolic dysfunction-associated
69 steatohepatitis (MASH) was proposed to supersede non-alcoholic steatohepatitis
70 (NASH). To optimize the management of these patients, it is crucial to comprehend
71 the similarities and differences between individuals with NASH and MASH.

72 **Methods:** We analyzed data from 13,846 participants in the third National Health and
73 Nutrition Examination Surveys, along with their linked mortality through 2019.

74 NASH and MASH were defined based on respective criteria. Survey-weight adjusted
75 multivariable Cox proportional model was used to examine mortality.

76 **Results:** The overall prevalence of steatohepatitis, NASH and MASH was 5.7%
77 (n=788), 4.1% (n=564) and 5.5% (n=763), respectively. Most individuals with NASH
78 (96.8%) could be categorized as MASH, but only 69.7% individuals with MASH
79 qualified as NASH. During a median follow-up of 27 years, individuals with MASH
80 exhibited a 53% higher risk of all-cause mortality (adjusted hazard ratio [aHR] 1.53,
81 95% CI 1.24-1.89). But individuals with NASH didn't show an association with all-
82 cause mortality after adjustment for metabolic risk factors (aHR 1.14, 95% CI 0.91-
83 1.44). Notably, individuals who met the criteria for MASH but not NASH
84 (NASH(-)/MASH(+)) had a higher risk of all-cause mortality (aHR 2.47, 95% CI
85 1.71-3.57) compared to those with NASH(+)/MASH(+) (aHR 1.22, 95% CI 0.97-
86 1.55). Moreover, advanced fibrosis was only associated with an increased risk of all-
87 cause mortality in individuals with MASH, not NASH.

88 **Conclusions:** MASH, rather than NASH, was associated with an elevated risk of all-

89 cause mortality after adjusting for metabolic risk factors. Well-designed prospective
90 studies are needed to assess and validate our findings.

91

92 **Key words:** NASH; MASH; mortality; NHANES III.

93

94 **Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI,
95 body mass index; CI, confidential intervals; FIB-4, fibrosis-4; HR, hazard ratio; HEI,
96 healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis;
97 MASLD, metabolic dysfunction associated steatotic liver disease; NAFLD,
98 nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NHANES III,
99 Third National Health and Nutrition Examination Survey; NFS, NAFLD fibrosis score;
100 PIR, poverty impact ratio.

101

102

103

104

105

106

107

108

109

110

111 **Introduction**

112 The most severe form of nonalcoholic fatty liver disease (NAFLD), non-alcoholic
113 steatohepatitis (NASH), significantly heightens the risk of developing cirrhosis and
114 liver cancer¹. Although the prevalence of NASH is relatively low compared to NAFLD,
115 it is witnessing a global upsurge². Recently, the nomenclature for NAFLD has been
116 updated to metabolic dysfunction associated steatotic liver disease (MASLD)³, with
117 NASH now designated as metabolic dysfunction-associated steatohepatitis (MASH).
118 However, whether MASH exhibits similar characteristics or clinical outcomes as
119 NASH remains ambiguous. Consequently, it is imperative to address these questions to
120 optimize management strategies for individuals with MASH.

121 Compared with NAFLD, MASLD places greater emphasis on the influence of
122 metabolic factors (meeting at least one of the five cardio-metabolic adult criteria,
123 without the constraints of alcohol consumption or viral hepatitis)³. Our previous study,
124 as well as those of others, have demonstrated a high concurrence between NAFLD and
125 MASLD⁴⁻⁸. Nevertheless, the similarities and differences between NASH and MASH
126 remain obscure. As per the definition³, it is speculated that individuals who met NASH
127 definition but not MASH might lack or exhibit mild metabolic risk factors, whereas,
128 those with MASH but not NASH are likely to present with more metabolic risk factors,
129 heavier alcohol consumption, or coexistence of viral hepatitis (hepatitis B or hepatitis
130 C). Although the incidence of discordant subgroups that fulfill the criteria for one but
131 not the other between NASH and MASH might be rare⁹, concrete data is currently
132 lacking.

133 A previous investigation utilizing the data from the Third National Health and Nutrition
134 Examination Survey (NHANES III) reported that NASH was not associated with an
135 elevated mortality rate over a 15-year follow-up period¹⁰. However, the potential impact
136 of extending the follow-up duration on the outcomes remains undefined. Moreover, it
137 is unclear whether MASH or the discordant subgroups exhibit differing risks of all-
138 cause and cause-specific mortality compared to NASH, necessitating further
139 exploration.

140 In this study, we employed data from NHANES III, with a 27-year follow-up period, to
141 compare the similarities and differences in clinical features and long-term mortality
142 between individuals with non-alcoholic steatohepatitis and metabolic dysfunction-
143 associated steatohepatitis.

144

145 **Participants and Methods**

146 **Study participants**

147 In this study, we utilized data from the NHANES III (1988-1994), a comprehensive,
148 stratified, clustered, multi-staged probability sampling design national survey that
149 accurately represents the entire US population¹¹. The outcomes of interviews, physical
150 examinations, and laboratory tests on participants with available liver ultrasonography
151 data were collected and analyzed. This mainly encompassed demographic indices (e.g.,
152 sex, age, race, education, smoking or drinking status, concomitant disease etc.),
153 anthropometric indices (e.g., body mass index (BMI), waist circumference, etc.), and
154 laboratory tests (e.g., alanine aminotransferase (ALT), aspartate aminotransferase

155 (AST), and triglyceride, etc.). The NHANES mortality follow-up was a prospective
156 study that dynamically assessed the vital status of all participants (≥ 20 years). Cause-
157 specific and all-cause mortality data were obtained from the National Death Index up
158 to December 2019¹². Detailed information on data collection and mortality evaluation
159 is provided in the supplementary materials. All individuals participating in NHANES
160 III signed informed consent.

161 **Definition of NASH, MASH, and Fibrosis**

162 As liver biopsies were not obtained in NHANES III, steatohepatitis was defined as mild
163 to severe hepatic steatosis with elevated liver enzymes levels based on a previous
164 study¹⁰. NASH was defined as the presence of steatohepatitis in the absence of
165 excessive alcohol consumption (≥ 20 g/d for females and ≥ 30 g/d for males) and/or other
166 liver diseases (such as viral hepatitis)¹⁰. MASH was defined by the presence of
167 steatohepatitis in conjunction with at least one of the five cardio-metabolic adult
168 criteria³. The detailed cardio-metabolic criteria are provided in the supplementary
169 materials. We further categorized concordant NASH(+)/MASH(+) individuals as those
170 who met both NASH and MASH definitions, while NASH(-)/MASH(-) individuals
171 satisfied neither NASH nor MASH criteria. For the discordant subgroups, individuals
172 fulfilling the NASH definition but not MASH were labeled as NASH(+)/MASH(-), and
173 vice versa for those meeting MASH but not NASH, who were defined as
174 NASH(-)/MASH(+). Finally, individuals without hepatic steatosis were designated as
175 the control group.

176 Due to the unavailability of liver biopsy for direct assessment of fibrosis stage, we

177 employed various non-invasive fibrosis scores as alternatives. The NAFLD fibrosis
178 score (NFS) and fibrosis-4 (FIB-4) score were selected based on prior studies^{13,14},
179 which can be further categorized into low, intermediate, and high probabilities for
180 advanced fibrosis. We defined advanced fibrosis as individuals presenting at least one
181 of the two scores indicating a high probability of advanced fibrosis.

182 **Statistical analysis**

183 The data are presented as median and interquartile range (IQR) for continuous variables,
184 unweighted frequency counts and weighted percentage for categorical variables. The
185 Wilcoxon test was employed for continuous variables, while the chi-square test was
186 utilized for categorical variables. Cox proportional hazards regression was employed to
187 estimate hazard ratios (HR) and 95% confidence intervals (CI) for deaths from all-
188 causes and cause-specific (cardiovascular disease and cancer). We utilized two models
189 with progressive degrees of adjustment: model 1 adjusted for demographic indices (sex,
190 age, race, marital status, education, poverty impact ratio (PIR), healthy eating index
191 (HEI) scores, sedentary lifestyle, and smoking status), while model 2 further adjusted
192 for metabolic risk factors (BMI, waist circumference, triglycerides, and high-density
193 lipoprotein cholesterol). For sensitivity analysis, firstly, to assess the impact of hepatic
194 steatosis severity, we excluded individuals with mild hepatic steatosis from those with
195 hepatic steatosis. Secondly, to avoid the potential confounding effect of viral hepatitis,
196 we excluded participants with hepatitis B or hepatitis C from the entire population. All
197 analyses were conducted using R (version 4.3.0; R Foundation for Statistical
198 Computing, Vienna, Austria), with the survey package employed to account for the

199 sampling weights and the complex survey design in the NHANES III.

200

201 **Results**

202 **Characteristics of individuals with NASH or MASH**

203 Of the 14,797 participants (20-74 years) who underwent hepatic/gallbladder ultrasound
204 examinations in the NHANES III, 941 individuals were excluded due to ungradable or
205 missing ultrasound images. In addition, 10 participants without follow-up data on
206 mortality were also excluded. Consequently, 13,846 participants from NHANES III
207 were included in this study (Table S1). The overall prevalence of steatohepatitis, NASH,
208 and MASH were 5.7% (n=788), 4.1% (n=564), and 5.5% (n=763), respectively. To
209 focus on steatohepatitis more effectively, individuals with hepatic steatosis and normal
210 liver enzyme levels (n=4,225) were further excluded from the entire population.
211 Ultimately, a total of 9,621 individuals were included for subsequent analyses.
212 Compared to individuals without hepatic steatosis, those with steatohepatitis were more
213 likely to be older, male, non-Hispanic black, less educated, poorer, have increased liver
214 enzyme levels, and exhibit metabolic abnormalities (Table 1).
215 Of note, a significant majority individuals with NASH (96.8%) can be classified as
216 MASH, yet only 69.7% of those with MASH can be qualified as NASH. Specifically,
217 of the 788 individuals diagnosed with steatohepatitis, 69.3% of the subjects were
218 assigned to the NASH(+)/MASH(+) subgroup, followed by NASH(-)/MASH(+),
219 NASH(+)/MASH(-), and NASH(-)/MASH(-) subgroups (27.5%, 2.3%, and 0.9%,
220 respectively; Figure 1). Notably, the subgroups characterized by MASH(+) exhibited

221 elevated coexisting metabolic risk factors, while those characterized by NASH(-)
222 demonstrated higher alcohol consumption and proportion of viral hepatitis, particularly
223 in the NASH(-)/MASH(+) subgroup (Table S2).

224 **All-cause and cause-specific mortality of individuals with NASH or MASH**

225 During the median follow-up period of 27.0 years (23.3-29.0), the cumulative mortality
226 rate from all-cause was 32.3% (3,105 deaths). Cause-specific mortality was attributed
227 to cardiovascular disease and cancer, accounting for 8.5% (816 deaths) and 8.1% (777
228 deaths), respectively. As shown in Table 2, individuals with NASH exhibited a 1.3-fold
229 increased risk of all-cause mortality compared to those without NASH (HR 1.29, 95%
230 CI 1.01-1.65). After adjusting for demographic and traditional risk factors, the
231 association between NASH and all-cause mortality remained significant (Model 1:
232 adjusted HR [aHR] 1.41, 95% CI 1.14-1.74). However, this association was attenuated
233 when further adjusting for metabolic risk factors (Model 2: aHR 1.14, 95% CI 0.91-
234 1.42). Notably, individuals with MASH exhibited higher all-cause mortality rate than
235 those without MASH in both models (Model 1: aHR 1.74, 95% CI 1.44-2.1; Model 2:
236 aHR 1.53, 95% CI 1.24-1.89). Intriguingly, subgroup analysis revealed that only the
237 NASH(-)/MASH(+) and NASH(-)/MASH(-) subgroups demonstrated significantly
238 elevated all-cause mortality rates compared to individuals without hepatic steatosis in
239 model 2 (aHR 2.47, 95% CI 1.71-3.57; aHR 3.65, 95% CI 1.48-9.04). The concordant
240 NASH(+)/MASH(+) subgroup showed no association with all-cause mortality after
241 further adjusting for metabolic risk factors (aHR 1.22, 95% CI 0.97-1.55). (Table 2)
242 Regarding cause-specific mortality, neither NASH nor MASH, nor their combined

243 subgroups demonstrated an association with cardiovascular mortality (Model 2: aHR
244 0.74-1.43) or cancer mortality (Model 2: aHR 1.25-1.87; Table 3).

245 **The effect of fibrosis on all-cause mortality in individuals with NASH or MASH**

246 Given that individuals with NASH have a higher propensity to develop fibrosis than
247 those with NAFLD¹⁵, we ponder whether such fibrosis augments the risk of all-cause
248 mortality in NASH or MASH patients. Interestingly, advanced fibrosis was merely
249 associated with an elevated risk of all-cause mortality in individuals with MASH, but
250 not NASH (Model 2: aHR 1.7, 95% CI 1.12-2.58, p=0.012; aHR 1.39, 95% CI 0.86-
251 2.22, p=0.2; Table 4). In particular, both the NFS and FIB-4 scores demonstrated a
252 graded increase in the risk of all-cause mortality in individuals with MASH. That is,
253 compared to the low probability subgroup, the high probability of advanced fibrosis
254 subgroup exhibited a higher risk of mortality than the intermediate probability subgroup
255 (NFS score: aHR 2.05, 95% CI 1.1-3.83; aHR 3.23, 95% CI 1.32-7.88; FIB-4 score:
256 aHR 1.42, 95% CI 0.87-2.32; aHR 2.62, 95% CI 1.26-5.41). A similar trend was also
257 observed in the NFS score of individuals with NASH (aHR 2.12, 95% CI 1.06-4.25;
258 aHR 2.32, 95% CI 1.02-5.3), whereas, no such discrepancy was detected in the FIB-4
259 score. (Table 4)

260 **Sensitivity analyses for individuals with NASH or MASH**

261 First, we wonder whether the hepatic steatosis degrees could affect the clinical
262 outcomes. After excluded individuals with mild hepatic steatosis from those with
263 hepatic steatosis, similar findings of mortality outcomes were observed (Table S3-5).

264 Second, to avoid the potential confounding effect of viral hepatitis, we excluded

265 individuals with hepatitis B or hepatitis C from the whole population. In this scenario,
266 the increased all-cause mortality was also observed in individuals with MASH, and
267 NASH(-)/MASH(+) and NASH(-)/MASH(-) subgroups (Table S6). For the cause-
268 specific mortality, the cardiovascular and cancer mortality were also not associated with
269 both NASH or MASH and their combinations (Table S7). Even though the high NFS
270 and FIB-4 scores subgroups still showed higher risk of all-cause mortality among
271 individuals with MASH, the difference was not significant in increased all-cause
272 mortality in MASH individuals with advanced fibrosis, after excluded participants with
273 viral hepatitis (Model 2: aHR 1.41, 95% CI 0.99-2.03, p=0.059; Table S8).

274 Firstly, we examined the potential impact of hepatic steatosis severity on clinical
275 outcomes. By excluding individuals with mild hepatic steatosis from those with hepatic
276 steatosis, we observed similar mortality outcomes (Table S3-5). Secondly, to mitigate
277 the potential confounding influence of viral hepatitis, we excluded individuals with
278 hepatitis B or hepatitis C from the study population. In this context, increased all-cause
279 mortality was also noted in individuals with MASH, as well as in the
280 NASH(-)/MASH(+) and NASH(-)/MASH(-) subgroups (Table S6). Regarding cause-
281 specific mortality, cardiovascular and cancer mortality were not associated with both
282 NASH and MASH, nor with their combinations (Table S7). Although individuals with
283 MASH in the high NFS and FIB-4 score subgroups exhibit a higher risk of all-cause
284 mortality, the increased risk of all-cause mortality among MASH patients with
285 advanced fibrosis does not reach statistical significance, after excluding participants
286 with viral hepatitis (Model 2: aHR 1.41, 95% CI 0.99-2.03, p=0.059; Table S8).

287

288 **Discussion**

289 The recent proposal of the new nomenclature MASH to replace NASH necessitates a
290 thorough understanding of the similarities and differences between individuals with
291 NASH and MASH, in order to optimize the management of these patients. In this study,
292 although patients with NASH exhibited similar clinical features regarding metabolic
293 risk factors compared to those with MASH, it was found that MASH, not NASH, was
294 significantly associated with an increased all-cause mortality after adjusting for
295 metabolic risk factors. Additionally, advanced fibrosis in patients with MASH was
296 associated with a higher risk of all-cause mortality compared to those with NASH.
297 These findings imply that independent of metabolic risk factors, there exists a strong
298 correlation between MASH and an increase in all-cause mortality.

299 NASH can contribute to progressive fibrosis, and in some cases, cirrhosis or even liver
300 cancer¹. However, a previous study found no correlation between NASH and an
301 increase in all-cause mortality following a 15-year follow-up in NHANES III¹⁰. Using
302 a longer follow-up period (27 years), we reiterated that NASH per se is not associated
303 with all-cause mortality after adjusting for metabolic risk factors. Notably, in contrast
304 to the previous study¹⁰, NASH increases the risk of all-cause mortality when only
305 adjusting for demographic and traditional risk factors (model 1), but not metabolic risk
306 factors. Although the definition of NASH does not encompass metabolic risk,
307 individuals with NASH exhibit similar metabolic characteristics to those with MASH
308 in this study. Consequently, caution should be exercised for the long-term prognosis of

309 individuals with NASH, particularly those with a high risk of concurrent conditions
310 (e.g., type 2 diabetes mellitus¹⁶ or liver cirrhosis¹⁷). Nevertheless, individuals with
311 MASH exhibit a 53% higher risk of all-cause mortality than those without MASH even
312 after adjusting for metabolic risks. This suggests that MASH can identify individuals
313 with a higher risk of all-cause mortality than NASH. Therefore, greater attention and
314 early intervention are warranted for those with MASH, such as lifestyle
315 modification^{18,19}, or other novel therapies^{20,21}.

316 When we further categorized individuals with steatohepatitis into four subgroups,
317 interesting findings regarding all-cause mortality emerged. In Model 1, individuals with
318 NASH(+)/MASH(+) exhibited a 47% increased risk of all-cause mortality, which
319 disappeared after further adjusting for metabolic risk factors. This suggests that
320 metabolic factors play a significant role in the elevation of all-cause mortality risk for
321 these individuals. Notably, individuals with NASH(-)/MASH(+) still exhibited a 2.47-
322 fold risk of all-cause mortality even after adjusting for metabolic risk factors. This
323 indicates that, beyond metabolic factors, heavy alcohol consumption and/or viral
324 hepatitis may have a more potent impact on the risk of all-cause mortality for MASH
325 patients^{22,23}. After excluding individuals with viral hepatitis in the sensitivity analysis,
326 the high all-cause mortality risk persisted. This suggests that significant alcohol
327 consumption, rather than viral hepatitis, could be responsible for the increased all-cause
328 mortality risk. However, this should be interpreted with caution due to the small sample
329 size. Larger studies are needed to verify these findings in the future. A similar
330 phenomenon was also observed in individuals with NASH(-)/MASH(-), although the

331 sample size was smaller. This subgroup represents a relatively small proportion of
332 individuals with concurrent liver disease but without metabolic comorbidities. After
333 excluding individuals with viral hepatitis, this discordant group may be attributed to
334 alcoholic steatohepatitis (ASH), which could contribute to the interpretation of the
335 increased risk of all-cause mortality²⁴. Therefore, based on these observations, it is
336 crucial to distinguish between MASH with concurrent liver disease and its absence in
337 future studies.

338 In this study, a significant majority of patients with NASH (96.8%) are classified as
339 MASH, with only 3.2% lacking metabolic risk factors. This finding is consistent with
340 a previous review⁹, and supports the retention and validity of historical data from
341 NASH clinical trials. However, the situation becomes distinct when reversed. As it is
342 not a prerequisite to exclude concurrent liver diseases for the diagnosis of MASH,
343 MASH may encompass a broader range of individuals with various liver disease
344 etiologies (viral, alcoholic, autoimmune, genetic, etc.), akin to MASLD³. Specifically,
345 only 69.7% of individuals with MASH can be confirmed as having NASH, suggesting
346 that 30.3% of these individuals harbor alternative etiologies (excessive alcohol
347 consumption and/or viral hepatitis) in this analysis. The gap may vary with differing
348 population selection. Moreover, in this context, it appears challenging to differentiate
349 between MASH and hepatitis induced by other etiologies (e.g., ASH or active viral
350 hepatitis). This could potentially impact the risk of all-cause mortality for these patients
351 directly, as mentioned above. From this aspect, it may be advantageous to appropriately
352 refine or qualify the new term of MASH in order to mitigate this ambiguity.

353 To our knowledge, no study has previously evaluated the association between MASH
354 and mortality. This is the strength of our study. However, there are several limitations
355 to our study. First, although this is a nationally representative study based on the
356 NHANES III dataset (1988-1994), the low prevalence of steatohepatitis at that time
357 resulted in a relatively small sample of patients with NASH or MASH. Large-sample
358 studies focusing on these patients are needed to validate our observations. Second,
359 steatohepatitis was not confirmed by liver biopsy but by ultrasound examination, which
360 may underestimate the prevalence and impact on clinical outcomes of individuals with
361 NASH or MASH²⁵. However, the advantages of ultrasound, such as safety, affordability,
362 sufficient sensitivity, and satisfactory specificity, make it suitable for use in large
363 population-based epidemiologic studies²⁶. Third, in the US population-based study, the
364 prevalence of viral hepatitis (especially hepatitis B) was low, therefore, the results in
365 this regard should be interpreted with caution. Further studies are needed to clarify the
366 specific effect of viral hepatitis on the mortality of individuals with MASH, especially
367 in high-prevalence areas of viral hepatitis, such as Asia and Africa²⁷.

368 In summary, our research demonstrates for the first time a significant association
369 between MASH and increased all-cause mortality, independently of metabolic and
370 demographic risk factors. In contrast, NASH exhibits a heightened risk of all-cause
371 mortality, while it becomes non-significant following adjustment for metabolic risk
372 factors. Moreover, it is crucial to differentiate between individuals with concomitant
373 liver disease and those without when studying MASH. In future, well-designed
374 prospective studies with large sample sizes are needed to assess and validate our

375 findings.

376

377 **Acknowledgement:** We gratefully acknowledge the contribution of the participants of
378 the NHANES cohort, research assistants, and facilitating personnel. And this work was
379 supported by the Science and technology research project of Chongqing Education
380 Commission (KJZD-K202300404), Remarkable Innovation-Clinical Research Project
381 and the DengFeng Program of the Second Affiliated Hospital of Chongqing Medical
382 University, and The First batch of key Disciplines on Public Health in Chongqing,
383 Health Commission of Chongqing, China.

384

385

386 **Conflict of interest statement:** The authors declare no conflicts of interest.

387

388 **Ethics approval statement**

389 The National Center for Health Statistics Research Ethics Review Board approved the
390 NHANES protocol.

391

392 **Data Availability Statement**

393 All data produced in the present study are available upon reasonable request to the
394 authors.

395

396 **Author contributions:** Rui Song, Zhao Li and Yingzhi Zhang was involved in

397 acquisition of data, data analysis and interpretation, drafting of the manuscript, and
398 study supervision. Jiahe Tan were involved in interpretation of data and critical
399 revision of the manuscript. Zhiwei Chen was involved in study concept and design,
400 interpretation of data, drafting of the manuscript, critical revision of the manuscript,
401 and study supervision. All authors contributed to the article and approved the
402 submitted version.

403

404 **Reference**

- 405 1. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related
406 HCC: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol*
407 *Hepatol.* 2021;18(4):223-238.
- 408 2. Brennan PN, Elsharkawy AM, Kendall TJ, Loomba R, Mann DA, Fallowfield
409 JA. Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-
410 centric approach. *Nat Rev Gastroenterol Hepatol.* 2023;20(10):679-688.
- 411 3. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus
412 statement on new fatty liver disease nomenclature. *J Hepatol.* 2023.
- 413 4. Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD, MAFLD and
414 MASLD characteristics and mortality outcomes in United States adults. *Liver*
415 *Int.* 2024;44(4):1051-1060.
- 416 5. Perazzo H, Pacheco AG, Griep RH. Changing from NAFLD through MAFLD
417 to MASLD: Similar prevalence and risk factors in a large Brazilian cohort. *J*
418 *Hepatol.* 2024;80(2):e72-e74.

- 419 6. Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet
420 MASLD criteria and natural history is therefore identical. *J Hepatol.*
421 2024;80(2):e76-e77.
- 422 7. Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data
423 under the new MASLD definition? *J Hepatol.* 2024;80(2):e54-e56.
- 424 8. Ratziu V, Boursier J. Confirmatory biomarker diagnostic studies are not needed
425 when transitioning from NAFLD to MASLD. *J Hepatol.* 2024;80(2):e51-e52.
- 426 9. Yeh ML, Yu ML. From nonalcoholic steatohepatitis, metabolic dysfunction-
427 associated fatty liver disease, to steatotic liver disease: Updates of nomenclature
428 and impact on clinical trials. *Clin Mol Hepatol.* 2023;29(4):969-972.
- 429 10. Lazo M, Hernaez R, Bonekamp S, et al. Non-alcoholic fatty liver disease and
430 mortality among US adults: prospective cohort study. *Bmj.* 2011;343:d6891.
- 431 11. CfDCaP NCfHS. Analytic and reporting guidelines: The Third National Health
432 and Nutrition Examination Survey, NHANES III (1988-94). 1996;
433 [https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/88-94-analytic-](https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/88-94-analytic-reporting-guidelines.pdf)
434 [reporting-guidelines.pdf](https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/88-94-analytic-reporting-guidelines.pdf) (Access on 2024.04.01).
- 435 12. Statistics NCfH. 2019 Public-Use Linked Mortality Files. 2022;
436 <https://www.cdc.gov/nchs/data-linkage/mortality-public.htm> (Access on
437 2024.04.01).
- 438 13. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a
439 noninvasive system that identifies liver fibrosis in patients with NAFLD.
440 *Hepatology.* 2007;45(4):846-854.

- 441 14. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison
442 of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver
443 disease. *Clin Gastroenterol Hepatol*. 2009;7(10):1104-1112.
- 444 15. Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. *Nat*
445 *Rev Gastroenterol Hepatol*. 2023;20(10):633-646.
- 446 16. En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty
447 liver disease in type 2 diabetes mellitus: an updated systematic review and meta-
448 analysis. *Gut*. 2023;72(11):2138-2148.
- 449 17. Lim WH, Ng CH, Tan D, et al. Natural history of NASH cirrhosis in liver
450 transplant waitlist registrants. *J Hepatol*. 2023;79(4):1015-1024.
- 451 18. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-
452 alcoholic fatty liver disease. *J Hepatol*. 2016;64(6):1388-1402.
- 453 19. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of
454 nonalcoholic fatty liver disease: Practice guidance from the American
455 Association for the Study of Liver Diseases. *Hepatology*. 2018;67(1):328-357.
- 456 20. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of
457 Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. *N Engl J Med*.
458 2021;384(12):1113-1124.
- 459 21. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in
460 Adults with Overweight or Obesity. *N Engl J Med*. 2021;384(11):989-1002.
- 461 22. Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. *Nat Rev Dis*
462 *Primers*. 2018;4(1):16.


- 463 23. You H, Wang F, Li T, et al. Guidelines for the Prevention and Treatment of
464 Chronic Hepatitis B (version 2022). *J Clin Transl Hepatol*. 2023;11(6):1425-
465 1442.
- 466 24. Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH.
467 *Dig Dis*. 2011;29(2):202-210.
- 468 25. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease.
469 *Gastroenterology*. 2002;123(5):1705-1725.
- 470 26. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging
471 in nonalcoholic fatty liver disease. *Gastroenterology*. 2002;123(3):745-750.
- 472 27. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global
473 burden of liver disease: 2023 update. *J Hepatol*. 2023;79(2):516-537.
- 474
- 475
- 476
- 477
- 478
- 479
- 480
- 481
- 482
- 483
- 484

485

486

487

488 **Figure and figure legend**



489

490 **Figure 1. Relative proportions of non-alcoholic steatohepatitis and metabolic**

491 **dysfunction-associated steatohepatitis.** NASH(+)/MASH(+) was defined as

492 individuals who met both NASH and MASH definitions. NASH(-)/MASH(-) was

493 defined as individuals who met neither NASH nor MASH definitions. For the

494 discordant subgroups, individuals meeting the definition of NASH but not MASH were

495 defined as NASH(+)/MASH(-), while those meeting with MASH but not NASH were

496 defined as NASH(-)/MASH(+).

497

498

499

500

Table 1. Baseline characteristics of individuals with NASH or MASH.

Characteristics	No hepatic steatosis (n=8,833)	Steatohepatitis (n=788)	P	NASH (n=564)	MASH (n=763)
Age (years)	38.0 (28.0, 51.0)	40.0 (33.0, 53.0)	0.003	40.0 (32.0, 52.0)	41.0 (33.0, 53.0)
Sex (male)	4,027 (47%)	445 (58%)	0.007	290 (55%)	429 (58%)
Race			<0.001		
Non-Hispanic white	3,293 (76%)	186 (66%)		138 (70%)	181 (67%)
Non-Hispanic black	2,829 (12%)	149 (8.6%)		318 (14%)	410 (14%)
Mexican-American	2,324 (4.8%)	421 (13%)		89 (6.6%)	141 (8.4%)
Others	387 (7.7%)	32 (12%)		19 (9.8%)	31 (11%)
Body mass index (kg/m ²)	24.7 (22.1, 27.6)	30.0 (26.6, 35.1)	<0.001	30.6 (27.0, 35.6)	30.3 (27.1, 35.2)
Waist circumference (cm)	88 (79, 96)	104 (94, 112)	<0.001	105 (94, 112)	104 (94, 112)
≥12 years education	5,716 (79%)	389 (70%)	<0.001	284 (74%)	373 (69%)
Marital status	5,445 (66%)	493 (63%)	0.3	374 (66%)	484 (63%)
PIR	2.9 (1.7, 4.3)	2.3 (1.1, 3.8)	0.016	2.4 (1.2, 3.9)	2.2 (1.1, 3.9)
HEI score	63 (54, 73)	61 (53, 73)	0.4	63 (53, 74)	61 (53, 72)
Hypertension	2,458 (23%)	334 (49%)	<0.001	237 (47%)	334 (51%)
Diabetes	581 (3.9%)	170 (20%)	<0.001	134 (21%)	170 (21%)
Smoking status			0.004		
Never	4,341 (46%)	377 (45%)		310 (50%)	363 (44%)
Past smoker	1,824 (22%)	195 (30%)		148 (33%)	191 (31%)
Current smoker	2,668 (32%)	216 (24%)		106 (17%)	209 (25%)
Alcohol consumption (g/d)	4 (1, 12)	8 (2, 28)	0.003	3 (0, 10)	8 (2, 28)
Viral hepatitis (HBV/HCV)	242 (2.2%)	96 (10%)	<0.001	0	96 (11%)
Sedentary lifestyle	2,420 (19%)	261 (23%)	0.2	199 (24%)	256 (23%)

Triglycerides (mg/dL)	1.1 (0.8, 1.6)	1.9 (1.2, 3.2)	<0.001	2.1 (1.4, 3.6)	2.0 (1.3, 3.3)
HDL-cholesterol (mg/dL)	1.3 (1.1, 1.6)	1.1 (0.9, 1.4)	<0.001	1.0 (0.9, 1.3)	1.1 (0.9, 1.4)
Glucose (mol/L)	5.1 (4.8, 5.4)	5.4 (5.1, 6.2)	<0.001	5.4 (5.0, 6.1)	5.5 (5.1, 6.2)
ALT (U/L)	13 (10, 18)	47 (37, 63)	<0.001	47 (37, 63)	47 (36, 63)
AST (U/L)	18 (16, 22)	39 (33, 53)	<0.001	38 (31, 48)	39 (32, 53)

Data are shown as the median (interquartile range) or unweighted frequency counts (weighted percentage) as appropriate. The Wilcoxon test for continuous variables and the Chi-square test for categorical variables were used in this analysis.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; NASH, nonalcoholic steatohepatitis; PIR, poverty impact ratio.

Table 2. Association among NASH or MASH status and all-cause mortality.

	N	n (deaths)	Univariable model		Multivariable Model 1		Multivariable Model 2	
			HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
No NASH	9057	2900	1		1		1	
NASH	564	205	1.29 (1.01-1.65)	0.042	1.41 (1.14-1.74)	0.001	1.14 (0.91-1.44)	0.2
No MASH	8858	2792	1		1		1	
MASH	763	313	1.8 (1.45-2.23)	<0.001	1.74 (1.44-2.1)	<0.001	1.53 (1.24-1.89)	<0.001
No hepatic steatosis	8833	2785	1		1		1	
NASH(+)/MASH(+)	546	203	1.41 (1.08-1.82)	0.01	1.47 (1.18-1.82)	<0.001	1.22 (0.97-1.55)	0.1
NASH(+)/MASH(-)	18	2	0.11 (0.02-0.61)	0.012	0.41 (0.07-2.44)	0.3	0.29 (0.03-2.77)	0.3
NASH(-)/MASH(+)	217	110	3.12 (2.39-4.06)	<0.001	2.51 (1.77-3.56)	<0.001	2.47 (1.71-3.57)	<0.001
NASH(-)/MASH(-)	7	5	4.02 (1.56-10.4)	0.004	3.01 (1.27-7.16)	0.012	3.65 (1.48-9.04)	0.005

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, race, marital status, education, PIR, HEI scores, sedentary lifestyle, and smoking status.

Multivariate model 2 was further adjusted for BMI, waist circumference, triglycerides, and high-density lipoprotein cholesterol in addition to model 1.

BMI, body mass index; CI, confidential intervals; HR, hazard ratio; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; NASH, nonalcoholic steatohepatitis; PIR, poverty impact ratio.

Table 3. Association among NASH or MASH status and cardiovascular disease and cancer-related mortality.

	N	n (deaths)	Univariable model		Multivariable Model 1		Multivariable Model 2	
			HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Cardiovascular mortality								
No NASH	9057	778	1		1		1	
NASH	564	38	1.03 (0.68-1.57)	0.9	1.14 (0.78-1.67)	0.5	0.74 (0.48-1.13)	0.2
No MASH	8858	763	1		1		1	
MASH	763	53	1.29 (0.9-1.87)	0.2	1.25 (0.87-1.78)	0.2	0.87 (0.58-1.32)	0.5
No hepatic steatosis	8833	762	1		1		1	
NASH(+)/MASH(+)	546	38	1.11 (0.73-1.69)	0.6	1.17 (0.8-1.7)	0.4	0.76 (0.5-1.15)	0.2
NASH(+)/MASH(-)	18	0	/	/	/	/	/	/
NASH(-)/MASH(+)	217	15	1.88 (0.92-3.85)	0.085	1.48 (0.57-3.82)	0.4	1.43 (0.53-3.87)	0.5
NASH(-)/MASH(-)	7	1	0.34 (0.04-3.13)	0.3	0.27 (0.03-2.88)	0.3	0.87 (0.08-9.15)	>0.9
Cancer mortality								
No NASH	9057	732	1		1		1	
NASH	564	45	1.04 (0.63-1.71)	0.9	1.25 (0.74-2.11)	0.4	1.25 (0.73-2.14)	0.4
No MASH	8858	704	1		1		1	
MASH	763	73	1.42 (0.97-2.07)	0.073	1.43 (0.94-2.19)	0.1	1.48 (0.91-2.4)	0.11
No hepatic steatosis	8833	704	1		1		1	
NASH(+)/MASH(+)	546	45	1.13 (0.68-1.86)	0.6	1.29 (0.76-2.19)	0.3	1.32 (0.76-2.27)	0.3
NASH(+)/MASH(-)	18	0	/	/	/	/	/	/
NASH(-)/MASH(+)	217	28	2.35 (1.33-4.13)	0.003	1.78 (0.97-3.24)	0.062	1.87 (0.97-3.59)	0.062
NASH(-)/MASH(-)	7	0	/	/	/	/	/	/

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, race, marital status, education, PIR, HEI scores, sedentary lifestyle, and smoking status.

Multivariate model 2 was further adjusted for BMI, waist circumference, triglycerides, and high-density lipoprotein cholesterol in addition to model 1.

BMI, body mass index; CI, confidential intervals; HR, hazard ratio; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; NASH, nonalcoholic steatohepatitis; PIR, poverty impact ratio.

Table 4. Association of advanced fibrosis status and all-cause mortality among individuals with NASH or MASH.

	N	n (deaths)	Univariable model		Multivariable Model 1		Multivariable Model 2	
			HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
NASH								
No advanced fibrosis	503	161	1		1		1	
Advanced fibrosis	55	43	4.39 (2.68-7.19)	<0.001	1.51 (0.92-2.47)	0.1	1.39 (0.86-2.22)	0.2
Low NFS	377	78	1		1		1	
Intermediate NFS	141	93	4.85 (2.60-9.03)	<0.001	2.65 (1.41-4.99)	0.002	2.12 (1.06-4.25)	0.033
High NFS	40	33	7.69 (3.55-16.7)	<0.001	3.11 (1.62-5.97)	<0.001	2.32 (1.02-5.30)	0.046
Low FIB-4	394	92	1		1		1	
Intermediate FIB-4	123	79	3.88 (2.31-6.52)	<0.001	1.45 (0.81-2.61)	0.2	1.35 (0.66-2.73)	0.4
High FIB-4	41	33	8.87 (5.36-14.7)	<0.001	1.62 (0.75-3.50)	0.2	1.95 (0.94-4.06)	0.074
MASH								
No advanced fibrosis	665	236	1		1		1	
Advanced fibrosis	91	75	4.37 (3.18-6.01)	<0.001	1.92 (1.27-2.91)	0.002	1.70 (1.12-2.58)	0.012
Low NFS	499	123	1		1		1	
Intermediate NFS	199	139	3.84 (2.38-6.19)	<0.001	2.55 (1.46-4.45)	<0.001	2.05 (1.10-3.83)	0.024
High NFS	58	49	7.38 (4.21-12.9)	<0.001	4.40 (2.21-8.73)	<0.001	3.23 (1.32-7.88)	0.01
Low FIB-4	501	126	1		1		1	
Intermediate FIB-4	180	121	3.05 (2.12-4.39)	<0.001	1.38 (0.89-2.14)	0.15	1.42 (0.87-2.32)	0.2
High FIB-4	75	64	8.01 (5.29-12.1)	<0.001	2.32 (1.26-4.27)	0.007	2.62 (1.26-5.41)	0.01

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, race, marital status, education, PIR, HEI scores, sedentary lifestyle, and smoking status.

Multivariate model 2 was further adjusted for BMI, waist circumference, triglycerides, and high-density lipoprotein cholesterol in addition to model 1.

BMI, body mass index; CI, confidential intervals; FIB-4, fibrosis-4; HR, hazard ratio; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; NASH, nonalcoholic steatohepatitis; NFS, NAFLD fibrosis score; PIR, poverty impact ratio.